Analyst Consensus ?
ConsensusBuy34 ratings
Bullish2573.5%
Neutral926.5%
Bearish00.0%
Labcorp Holdings Inc. · LH · FY2026 Q1 · Calendar Q2 2026
Labcorp Q1 2026: Revenue and EPS Beat Estimates, Full-Year Guidance Raised
Labcorp's Q1 FY2026 reinforced the growth narrative from its full-year 2025 report. Both Diagnostics and Biopharma Laboratory Services contributed to solid enterprise revenue growth, driven by specialty and esoteric testing demand. Management raised the midpoint of full-year revenue and EPS guidance, signaling confidence that acquisitions, AI-driven efficiency gains, and specialty test expansion will offset weather-related softness and regulatory uncertainty. The company's broad partnership ecosystem and consumer health platform additions provide additional growth vectors. Policy risks around PAMA, CMS CRUSH, and ACA exchange enrollment warrant close monitoring but did not materially impair the quarter.
Reported Before market openNYSEHealthcare
$25.19B market cap
100quality score
Company context
Snapshot as of publicationLabcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
Earnings scorecard
Reported versus consensus
Reported EPS
$4.25
Consensus $4
EPS surprise
+3.4%
Reported versus consensus
Reported revenue
$3.54B
Consensus $3.51B
Revenue surprise
+0.8%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$315.53Current
$240Low
$302.33Average
$370High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Baird | Outperform | Outperform | Maintain | Jul 13, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 13, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Apr 8, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Feb 24, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Feb 18, 2026 |
| UBS | Buy | Buy | Maintain | Oct 29, 2025 |
| Mizuho | Outperform | Outperform | Maintain | Oct 17, 2025 |
| Barclays | Equal Weight | Equal Weight | Maintain | Oct 2, 2025 |
| Truist Securities | Buy | Buy | Maintain | Jul 25, 2025 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 25, 2025 |
| Citigroup | Buy | Neutral | Upgrade | Mar 4, 2025 |
| Jefferies | Buy | Buy | Maintain | Feb 6, 2025 |
| HSBC | Buy | Hold | Upgrade | Oct 30, 2024 |
| Deutsche Bank | Hold | Hold | Maintain | Aug 2, 2024 |
| Argus Research | Buy | Hold | Upgrade | Mar 25, 2024 |
| Wells Fargo | Overweight | Overweight | Maintain | Aug 14, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 2, 2023 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Jul 13, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | May 21, 2020 |
| KeyBanc | Overweight | Overweight | Maintain | Mar 30, 2020 |
| Bank of America | Neutral | Underperform | Upgrade | Jul 16, 2019 |
| Canaccord Genuity | Hold | Hold | Maintain | May 2, 2019 |
| Goldman Sachs | Buy | Conviction Buy | Downgrade | Nov 30, 2018 |
| Argus | Hold | Buy | Downgrade | Oct 30, 2018 |
| JMP Securities | Outperform | Market Outperform | Maintain | Mar 27, 2015 |
| Maxim Group | Buy | Buy | Maintain | Mar 24, 2015 |
| PiperJaffray | Overweight | Neutral | Upgrade | Feb 23, 2015 |
| Raymond James | Outperform | Underperform | Upgrade | Jan 2, 2015 |
| FBR Capital | Market Perform | Market Perform | Maintain | Oct 28, 2014 |
| William Blair | Outperform | Market Perform | Upgrade | Jul 17, 2014 |
| Cantor Fitzgerald | Buy | Buy | Maintain | May 9, 2014 |
| ISI Group | Neutral | Neutral | Maintain | Nov 19, 2013 |
| Craig-Hallum | Buy | Buy | Maintain | Aug 28, 2013 |
| Oppenheimer | Perform | Perform | Maintain | Jan 28, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $315.53. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Robert W. Baird | Eric Coldwell | $334 | $255.97 | +5.9% | May 1, 2026 |
| Evercore ISI | Analyst unavailable | $300 | $274.72 | -4.9% | Apr 8, 2026 |
| Piper Sandler | David Westenberg | $300 | $285.3 | -4.9% | Feb 24, 2026 |
| Robert W. Baird | Analyst unavailable | $326 | $276.67 | +3.3% | Feb 18, 2026 |
| Robert W. Baird | Analyst unavailable | $313 | $259.18 | -0.8% | Jan 14, 2026 |
| UBS | Kevin Caliendo | $320 | $253.74 | +1.4% | Oct 29, 2025 |
| Robert W. Baird | Analyst unavailable | $304 | $259.69 | -3.7% | Oct 29, 2025 |
| Leerink Partners | Michael Cherny | $342 | $261.62 | +8.4% | Oct 28, 2025 |
| UBS | Analyst unavailable | $325 | $285.93 | +3.0% | Oct 17, 2025 |
| Mizuho Securities | Ann Hynes | $320 | $283.71 | +1.4% | Oct 17, 2025 |
| Truist Financial | Analyst unavailable | $320 | $278.42 | +1.4% | Oct 14, 2025 |
| Evercore ISI | Analyst unavailable | $305 | $279.44 | -3.3% | Oct 3, 2025 |
| Barclays | Analyst unavailable | $290 | $279.06 | -8.1% | Oct 2, 2025 |
| Robert W. Baird | Analyst unavailable | $311 | $276.11 | -1.4% | Aug 25, 2025 |
| UBS | Kevin Caliendo | $305 | $264.96 | -3.3% | Jul 25, 2025 |
| Barclays | Analyst unavailable | $275 | $258.7 | -12.8% | Jun 25, 2025 |
| Barclays | Luke Sergott | $271 | $247.86 | -14.1% | Feb 3, 2025 |
| Evercore ISI | Elizabeth Anderson | $240 | $224.72 | -23.9% | Sep 24, 2024 |
| Jefferies | Brian Tanquilut | $265 | $222.22 | -16.0% | Sep 23, 2024 |
| Bank of America Securities | Michael Ryskin | $260 | $236 | -17.6% | Aug 5, 2024 |
| Robert W. Baird | Eric Coldwell | $277 | $235.67 | -12.2% | Aug 2, 2024 |
| Argus Research | David Toung | $250 | $212.5 | -20.8% | Mar 25, 2024 |
| Morgan Stanley | Analyst unavailable | $303 | $241.42 | -4.0% | Jan 6, 2023 |
| Credit Suisse | Analyst unavailable | $305 | $238 | -3.3% | Nov 23, 2022 |
| Mizuho Securities | Analyst unavailable | $296 | $254.72 | -6.2% | Jul 29, 2022 |
| Deutsche Bank | Analyst unavailable | $265 | $245.45 | -16.0% | May 3, 2022 |
| Credit Suisse | Analyst unavailable | $312 | $240.28 | -1.1% | May 2, 2022 |
| Wells Fargo | Analyst unavailable | $315 | $266.12 | -0.2% | Apr 25, 2022 |
| Bank of America Securities | Derik de Bruin | $370 | $276.26 | +17.3% | Feb 11, 2022 |
| Deutsche Bank | Pito Chickering | $294 | $270.08 | -6.8% | Jan 28, 2022 |
| Truist Financial | David S Macdonald | $350 | $296.15 | +10.9% | Jul 30, 2021 |
| Argus Research | Jasper Hellweg | $295 | $269.61 | -6.5% | May 20, 2021 |
Track every rating change on LH the moment it posts. Free to start.
Start freeMarket reaction
prior-close to event-session close
Stock move
-0.1%
Event window
SPY move
+1.0%
Same window
Abnormal move
-1.1%
Stock minus SPY
Volume
2.5×
Versus trailing sessions
Subsequent drift
+1.3%
Up to 20 sessions
LHSPY benchmark
Follow LH with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Compared to the prior quarter where full-year 2026 guidance was introduced and maintained, management now raised the midpoint of both revenue and EPS guidance following a Q1 beat. Capex outlook shifted from increasing to stable. New acquisitions including Crouse Health's Laboratory Alliance and the pending Parkview Health outreach labs are incremental to the prior quarter's announced pipeline. The MyLabcorp mobile app with AI assistant is a new product launch. Weather emerged as a near-term headwind, reducing organic volume growth. CMS CRUSH policy was added as a new regulatory concern alongside existing PAMA and ACA enrollment issues.
Guidance delta
Prior quarter: maintained. Current quarter: raised. Management raised the midpoint of full-year revenue and EPS guidance, citing stronger-than-expected specialty testing demand and solid Q1 execution.
Key takeaways
- Q1 revenue and margins beat expectations, with Diagnostics up 5% and Biopharma Laboratory Services up 8.2%
- Management raised the midpoint of full-year revenue and EPS guidance on strong specialty-test demand
- Strategic collaborations with CHOP, Illumina, PathAI, AWS/Datavant, and Optum.ai remain central to the growth strategy
- Weather and policy issues including ACA, CMS CRUSH, and PAMA are short-term headwinds but did not derail the quarter
- Consumer health initiatives and the MyLabcorp platform are accelerating double-digit growth in that segment
Management priorities
- Launch MyLabcorp mobile app with AI assistant for results interpretation and appointment scheduling in May
- Expand AI collaborations with PathAI, AWS/Datavant, Optum.ai, and Illumina across pathology and lab operations
- Open new strategic facility to support Central Labs growth and clinical-trial demand
- Close pending acquisition of Parkview Health outreach labs in Indiana and Northwest Ohio
- Hold Investor Day on September 10 to detail longer-term strategy
Related earnings events
HealthcareHCA · FY2026 Q2 · Calendar Q3 2026HCA Q2 2026: Payer-Mix Shift Hits EBITDA, Florida Medicaid Boosts, $7B Capex UnveiledWST · FY2026 Q2 · Calendar Q3 2026West Pharmaceutical Q2 2026: EPS and Revenue Beat, Guidance Raised AgainDGX · FY2026 Q2 · Calendar Q3 2026Quest Diagnostics Beats on Volume and AI Automation, Raises Full-Year Guidance
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-30T20:11:13.633867+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-30T20:11:13.631136+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.